Skip to main content

Table 3 Clinical, histopathological and metabolic features of NF-PNETs

From: Prediction of the aggressiveness of non-functional pancreatic neuroendocrine tumors based on the dual-tracer PET/CT

 18F-FDG-positive SUVmax range 3.0–8.618F-FDG-negative SUVmax range 0.8–3.2P68Ga-DOTANOC-positive SUVmax range 8.7–104.768Ga-DOTANOC-negative SUVmax 4.4P
Sex  1.000  1.000
 Male7/11 (64)13/20 (65) 19/301/1 
 Female4/11 (36)7/20 (35) 11/300/1 
Age, years67 (38–78)68 (50–71)1.00066 (47–72)700.903
Primary tumor size, mm33 (23–90)20 (13–30)0.02324 (14-38)330.581
Asymptomatic8/11 (73)20/20 (100)0.03727/301/11.000
CgA  0.258  0.516
 Strongly positive2/11 (18)1/20 (5) 3/300/1 
 Weakly positive6/11 (55)9/20 (45) 15/300/1 
 Negative3/11 (27)11/20 (50) 12/301/1 
Location  0.630  1.000
 Head6/11 (55)6/20 (30) 11/301/1 
 Body0/11 (0)2/20 (10) 2/300/1 
 Tail3/11 (27)7/20 (35) 10/300/1 
 Multifocal2/11 (18)5/20 (25) 7/300/1 
Grade*  0.023  1.000
 G13/9 (33)13/16 (81) 15/241/1 
 G25/9 (56)3/16 (19) 8/240/1 
 G31/9 (11)0/16 (0) 1/240/1 
Ki-674.0 (1.5–11.0)2.0 (1.0–2.5)0.0512.0 (1.0–4.5)1.00.384
68Ga-DOTANOC-positive10/11 (91%)20/20 (100%)0.355   
18FDG-positive   10/30 (33%)1/1 (100%)0.355
LN+2/8 (33)4/11 (36)1.0005/301/10.316
  1. Categorical variables are expressed as n (%) and continuous variables are reported as median values (IQR)
  2. Abbreviations: CgA, circulating chromogranin A, Strongly positive indicates S-CgA = 13.5 nmol/L or P-CgA 9–37 nmol/L, weakly positive indicates S-CgA 2.2–4.7 nmol/L or P-CgA 3.0–4.8 nmol/L and negative indicates S-CgA < 2.1 nmol/L or P-CgA < 3.0 nmol/L; LN+, lymph node metastases
  3. *Lesion analysis (histologically confirmed, n = 25)
  4. Follow-up patients, biopsied patients and one patient who underwent enucleation were excluded because it was not possible to assess their LN+